<DOC>
	<DOCNO>NCT02441101</DOCNO>
	<brief_summary>This clinical study design test whether new pace therapy would lead improvement heart function , symptom quality life specific group heart failure patient . This group unique electrical conduction problem ( Right Bundle Branch Block ) respond well current available pacing therapy .</brief_summary>
	<brief_title>Right Ventricular Septal Pacing Patients With Right Bundle Branch Block Heart Failure ( The SPARK Trial )</brief_title>
	<detailed_description>This pilot clinical trial randomize single blind cross trial . Each subject undergo three study stage . Subject randomize initially either two arm ; experimental placebo , follow 3 month first stage ass outcome . In second stage , arm transition two month , intervention free , wash period . Finally , third stage arm cross subject follow additional 3 month outcomes assessment .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Bundle-Branch Block</mesh_term>
	<mesh_term>Heart Block</mesh_term>
	<criteria>Cardiomyopathy ; ischemic nonischemic optimal medical therapy per current heart failure treatment guideline least 3 month . LVEF &lt; 35 % transthoracic echocardiogram assessment Prior implantation pacemaker/defibrillator least atrial RV mid septal lead . Atrial lead waive RV lead atrial sense capabilities* Normal sinus rhythm enrollment RBBB QRS duration &gt; 120 msec 12 lead surface EKG . PR interval &lt; 250 msec 12 lead surface EKG Subjects biventricular pacemaker/ICD eligible enrollment LV lead pace function turn subject 's primary cardiologist prior study enrollment least 3 month ( could due lead malfunction decision deactivate LV pace therapy reason per primary cardiologist discretion ) Age young 18 year old Pregnancy Acute Myocardial infarction within 6 month entry study Inotrope dependent heart failure condition Left ventricular assist device heart transplantation Any known condition heart failure could limit survival &lt; 6 month . Atrial fibrillation flutter burden &gt; 10 % time within last 6 month Atrioventricular node disease require ventricular pacemaker support &gt; 10 % time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cardiac Resynchronization therapy</keyword>
</DOC>